Assessment of CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management

Credit: Oncotarget (2024). DOI: 10.18632/oncotarget.28566 Conventional tumor markers may serve as adjuncts in non-small cell lung cancer (NSCLC) management. In a new study, researchers Scott Strum, Mark Vincent, Meghan Gipson, Eric McArthur, and Daniel Breadner from the Schulich School of Medicine and Dentistry, London Health Sciences Center, and Royal College of Surgeons in Ireland analyzed whether three tumor markers (CEA, CA19-9, and CA-125) held associations with radiographic and clinical outcomes in NSCLC. “The aim of this retrospective study was to provide additional evidence for the clinical use of conventional serum Read More

Related posts:

  1. Development of new techniques and clinical applications of liquid biopsy in lung cancer management
  2. HMN: Lung cancer statistics 2024 | in 2025
  3. Study finds just 18% of people who need lung cancer screening get it
  4. Why many lung cancer patients who have never smoked have worse outcomes
  5. E-cigarette use linked to lower use of lung cancer screening
  6. New survey finds cancer drug shortage management remains a moving target, impacting clinical trials
  7. Researchers say AI blood test provides a reliable way to identify lung cancer
  8. Nano-immunotherapy developed to improve lung cancer treatment

Leave a Reply

Your email address will not be published. Required fields are marked *